Barclays PLC Acquires 120,789 Shares of Annexon, Inc. (NASDAQ:ANNX)

Barclays PLC grew its holdings in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) by 212.0% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 177,765 shares of the company's stock after buying an additional 120,789 shares during the period. Barclays PLC owned approximately 0.17% of Annexon worth $1,052,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. Sandia Investment Management LP bought a new position in shares of Annexon in the second quarter valued at approximately $49,000. Victory Capital Management Inc. bought a new position in Annexon during the 2nd quarter valued at $51,000. Principal Financial Group Inc. purchased a new position in Annexon during the 2nd quarter worth $56,000. Quarry LP bought a new stake in shares of Annexon in the 3rd quarter worth $118,000. Finally, Allegheny Financial Group LTD grew its stake in shares of Annexon by 16.1% in the 2nd quarter. Allegheny Financial Group LTD now owns 25,200 shares of the company's stock worth $123,000 after acquiring an additional 3,500 shares in the last quarter.

Annexon Stock Performance

ANNX remained flat at $5.13 during trading on Tuesday. 1,039,359 shares of the company traded hands, compared to its average volume of 1,776,754. Annexon, Inc. has a one year low of $3.86 and a one year high of $8.40. The firm's 50 day moving average price is $5.85 and its two-hundred day moving average price is $5.94. The firm has a market capitalization of $546.83 million, a price-to-earnings ratio of -4.89 and a beta of 1.10.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on ANNX shares. Cantor Fitzgerald reissued an "overweight" rating on shares of Annexon in a research report on Friday, November 15th. HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Annexon in a research report on Tuesday, December 17th. Finally, Needham & Company LLC restated a "buy" rating and issued a $16.00 target price on shares of Annexon in a research note on Friday, November 15th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $15.80.

Insider Buying and Selling at Annexon

In other Annexon news, EVP Ted Yednock sold 5,408 shares of the firm's stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $7.41, for a total value of $40,073.28. Following the completion of the sale, the executive vice president now directly owns 71,365 shares of the company's stock, valued at $528,814.65. This trade represents a 7.04 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 12.67% of the company's stock.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.